Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.
    Blood. 2017 Jan 26;129(4):424-447

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.
    Blood. 2018 Mar 22;131(12):1275-1291

  • Measurable residual disease testing in acute myeloid leukaemia.
    Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. 
    Leukemia. 2017 Jul;31(7):1482-1490